Investigating Asthma After Coccidioidomycosis Among Patients With Commercial Health Insurance, United States, 2017–2022
Increased healthcare provider awareness of asthma as a potential coccidioidomycosis complication could benefit patients, especially female patients and patients with severe pulmonary infection.
Authors
- Angela Haczku (ORCID: https://orcid.org/0000-0002-1301-4941)
- Mitsuru Toda (ORCID: https://orcid.org/0000-0002-5904-6658)
- Amir A. Zeki (ORCID: https://orcid.org/0000-0001-8901-588X)
- Dallas J. Smith (ORCID: https://orcid.org/0000-0001-5707-528X)
- Kaitlin Benedict (ORCID: https://orcid.org/0000-0003-0458-2493)
- George R. Thompson (ORCID: https://orcid.org/0000-0001-8518-5750)
- Joy Hsu (ORCID: https://orcid.org/0000-0001-8410-9334)
- Nicholas J. Kenyon (ORCID: https://orcid.org/0000-0001-8839-4400)
Institutions
- Centers for Disease Control and Prevention (US)
- National Center for Environmental Health (US)
- National Center for Emerging and Zoonotic Infectious Diseases (US)
- VA Northern California Health Care System (US)
- University of California, Davis (US)
Publication Details
- Journal
- Mycoses
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/myc.70033
- Citations
- 2
- Primary Topic
- Fungal Infections and Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Pfizer
- Sanofi
- Regeneron Pharmaceuticals
- Cidara Therapeutics
- Astellas Pharma
- Centers for Disease Control and Prevention